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Basal cell carcinomas following roentgen 
therapy of ankylosing spondylitis 
To the Editor: 
Since 1902, ionizing radiation has been known as 
an important factor in the development of carcinoma in 
human skin (1). This is a report of multiple basal cell 
carcinomas in the lumbosacral area in a patient who 
had completed radiotherapy for ankylosing spondylitis 
22 years previously. 
In 1950 a 23-year-old man developed back pain 
that was diagnosed as ankylosing spondylitis. In 1951 
his physicians administered radiation therapy totaling 
400 scattered roentgens to the sacral, 1,000 to the lum- 
bar, and 200 to the thoracic spinal region. In 1956 he re- 
ceived additional irradiation of 400 roentgens in air to 
each of five fields: cervical, upper thoracic, lower tho- 
racic, lumbar, and sacroilac. In 1976 a lumbar spinal 
osteotomy was carried out for the relief of severe ky- 
phosis. His cutaneous wound healed quickly and une- 
ventfully. 
In 1978, while the patient was hospitalized for 
newly discovered diabetes mellitus, a cluster of scaly 
pinkish papules scattered in the lumbosacral area on 
both sides and away from the osteotomy scar was noted. 
Biopsy of five of these lesions showed nests of basal cell 
carcinoma budding downward to the dermis. The le- 
sions were treated with electrofulguration and curettage. 
Figure 1 shows the scars left by this procedure. In 1980, 
three new basal cell carcinomas were discovered within 
the area enclosed by the previous lesions. 
Roentgen therapy for ankylosing spondylitis was 
introduced in 1930 (2) and was thenceforth applied in 
large numbers of cases until the late 1950s. The size of 
the recommended roentgen dosage was never clearly 
standardized. Smyth, Freyberg, and Lampe originally 
used 600 rads per total field dose, but later reduced this 
to 300 rads because temporary leukopenia developed in 
a few patients (3). Commonly, as in our patient, addi- 
tional treatment was given as symptoms recurred or de- 
veloped in new areas. Any portion or all of the spine 
and the sacroiliac joints were treated, as well as the hips 
and shoulders in a small number of patients. Irradiation 
therapy for ankylosing spondylitis fell into disrepute af- 
ter an association with leukemia was published in 1955 
that estimated the risk of leukemia at ten times that of 
nonirradiated patients or of the general population (4). 
Five patients who received radiotherapy for an- 
Figure 1. Lumbar osteotomy scar and sites of five basal cell carcino- 
mas (arrows). 
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Table 1. Basal cell carcinomas following irradiation of spine for ankylosing spondylitis 
Length of No. of Skin dose, 
Patients radiotherapy treatments kV rads Area treated Latent period* 
Sarkany et a1 (5) 10 years 158 15 8750 Spine 23 
1 140 
121 15 5425 Front of trunk and 
66 15 spine; remainder 
100 area lateral to central 
140 Of trunk 
2 16 years 133 130 7980 Back of trunk 28 
3 2 years 36 100 2000 Back of trunk 23 
4 6 years 30 220 3335 Spine 20 
5 2 months 8 220 1200 Spine I 1  
Present report 5 years 2 200 400 Cervical spine 21 
600 Thoracic spine 
1400 Lumbar spine 
800 Sacrum and sacroiliac 
* Years elapsing between start of radiotherapy and diagnosis of tumors. 
kylosing spondylitis developed multiple skin tumors on 
the back 11-28 years later (5). Four were treated with 
2,000 or more rads and widefield irradiation, plus local 
irradiation of the spine (Table 1). Development of carci- 
nomas in the fifth patient who received 1200 rads and 
our patient who received a total of 1400 rads over the 
lumbar spine indicates that the population at risk in- 
cludes patients treated with dosages employed com- 
monly in North America. 
Another report described patients with back pain 
(1 case), lumbar disc disease (1 case), and ankylosing 
spondylitis (1 case) who developed basal cell carcino- 
mas as well as fibroepitheliomas of Pinkus (26, 26, and 
19 years later, respectively) within exposed areas after 
unspecified amounts of therapeutic irradiation (6). 
Basal cell carcinomas ascribed to radiation are 
usually encountered on the face, neck, and scalp, with 
latent periods averaging 20-25 years between irradia- 
tion therapy and diagnosis (7). Following treatment of 
ringworm of the scalp, this latent period may be as short 
as 7 years (8). However, a study of 26 such cases showed 
an interval averaging 45 years (9). 
The latent period for irradiation-induced cutane- 
ous neoplasm varies inversely with the dose, ranging 
from 7 weeks to 56 years (10). Squamous cell carcino- 
mas are associated with large exposure and skin ulcer- 
ation. On the other hand, basal cell carcinomas pre- 
dominate following smaller doses, with or without 
history of radiation dermatitis, and often occur in skin 
that is otherwise clinically normal (10). 
A survey for causes of mortality in a series of 
14,544 patients with ankylosing spondylitis carried out 
5-25 years after radiotherapy did not disclose deaths 
from skin tumors (1 1). Apparently, a survey for tumors 
in irradiated skin was not performed in this patient 
study as of 1972 (10). Extrapolating from the remark- 
ably delayed onset of cutaneous neoplasia following ir- 
radiation of the scalp, it appears that patients treated for 
ankylosing spondylitis 25-50 years ago may still be sus- 
ceptible to this complication. The skin at sites of irradia- 
tion should be examined carefully whenever these pa- 
tients are encountered. 
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Late appearing nitritoid reactions 
To The Editor: 
Podell et a1 in their article “Pulmonary Toxicity 
with Gold Therapy” (Arthritis Rheum 23:347-350, 
1980) note that nitritoid reactions to the thiomalate 
preparation are common and occur early in the course 
of treatment. I should like to report a somewhat differ- 
ent experience. All my patients are begun on the 
thiomalate preparation, and in only three has a nitritoid 
response appeared. In one case, it occurred at 1,000 mg. 
But in 2 instances the reaction was very late, as the fol- 
lowing descriptions indicate. 
CS, a 75-year-old woman, began gold injections 
9 years ago. After 8 years and having received 6,225 mg 
of gold sodium thiomalate, she had a typical nitritoid 
reaction. She was switched to the thioglucose prepara- 
tion and has had no further problem. An electrocardio- 
gram (ECG) revealed no acute changes. 
BB, a 76-year-old woman, began treatment 14 
years ago. There was an excellent response for several 
years, followed by a gradual relapse. After 9 years, gold 
injections were discontinued after a total of 7,600 mg, 
and various other modalities were tried without success. 
After a year, gold sodium thiomalate was resumed 
which resulted in considerable improvement. After 2% 
years and a total of 3,300 mg, a typical nitritoid reaction 
occurred. With the thioglucose preparation, there has 
been no problem. An ECG revealed no acute changes. 
The above reports are intended to alert the phy- 
sician employing gold salt injections to be aware of very 
late appearing nitritoid reactions with the gold sodium 
t hiomalate . 
SELVAN DAVISON, MD, FACP 
Rheumatology Division 
Department of Medicine 
The Mount Sinai Medical Center 
New York, NY 10029 
Secondary amyloidosis and sicca syndrome 
To The Editor: 
Simon and Moustopoulos recently reported a 
case of sicca syndrome in a patient with primary amy- 
loidosis and monoclonal gammopathy due to amyloid 
invasion of the lacrimal and salivary glands (Arthritis 
Rheum 22:932-934, 1979). We report here a patient 
with sicca syndrome due to secondary amyloidosis. 
The patient is a 57-year-old white woman with 
severe, long-standing, seronegative, erosive rheumatoid 
disease. She recently noted the onset of severe xero- 
stomia and swollen cheeks. Examination revealed bilat- 
eral non-tender s w e h g  of the parotid glands, a large 
tongue, and a normal response to the Schirmer tear test. 
Lip biopsy demonstrated diffuse deposition of amyloid 
around atrophied salivary acini, normal salivary ducts, 
and no inflammatory infiltrate. Serum protein elec- 
trophoresis revealed no monoclonal spike, and urine 
was negative for Bence Jones protein. 
This patient fulfills the necessary two of three 
criteria for sicca syndrome-parotid swelling and xero- 
stomia. There were no signs of keratoconjunctivitis. Her 
amyloidosis is most likely secondary to severe rheuma- 
toid disease of long duration. She thus represents a case 
of sicca syndrome due to secondary amyloidosis. 
M. A. CATALANO, MD 
J. H. VAUGHAN, MD 
Scripps Clinic and Research Foundation 
10666 N. Torrey Pines Road 
La Jolla, CA 92037 
Buerger’s disease and multicentric 
fibromuscular hyperplasia mimicking 
Takayasu’s arteritis 
To the Editor: 
Thromboangiitis obliterans (Buerger’s disease) is 
an unusual vascular disorder of unknown etiology that 
has been recognized infrequently in females. We have 
recently treated a woman with severe Buerger’s disease 
in whom roentgenographic studies demonstrated mul- 
tiple obstructive lesions of the aorta and its branches. 
Surgical exploration of a carotid lesion was consistent 
with fibromuscular hyperplasia. The occurrence of co- 
existing Buerger’s disease and multicentric fibromuscu- 
lar hyperplasia is unique and initially suggested a dif- 
fuse form of vasculitis. 
A 33-year-old white woman was admitted to 
Madigan Army Medical Center because of ischemic ne- 
crosis of her right foot and hypertension. An arteri- 
